A VHL gene intragenic mutation was noted in 21 cases (45.6%), including 1 case with a biallelic mutation (case n°38, Table 4).
While previously noted inter-strain differences were confirmed for different manifestations of caring behavior, self-maintenance and neglecting behaviors as well as the pup retrieval test, no strain-independent effect of the GR mutation was noted.
Moreover, a VHL gene mutation was noted in 1 of the 6 non informative ccRCCs (case n° 42, Table 4), and in case n°52, not available for LOH analysis because of the absence of normal tissue specimen.
KRAS mutation status was evaluated in 205 patients, and mutation was noted in 88 of those patients (42.9%).
Those which appear to contribute some insight into pathogenic mechanisms (cobblestone malformation, GPR56 mutation) are noted above.
By week 48 in ARTEMIS, patients experiencing viral rebound had not developed any IAS-USA PI resistance mutations, 31 although one NRTI mutation was noted, M184V.
KRAS mutation status was evaluated in 205 patients and mutation was noted in 88 of those patients (42.9%), in concordance with the mutation rate of KRAS in CRC (35%to42%2%) [ 19].
The pncA sequences of the isolates from animals and humans were identical to those of M. tuberculosis H37Rv; in codon 38 of the Rv2042c gene, directly upstream from pncA, a GTC to GGC (Ser→Ala) mutation was noted in all 22 isolates; the partial Rv2042c sequence is stored in GenBank (accession no. JF417976).
However, no difference in prevalence of BRCA1 and BRCA2 mutations is noted among women who develop isolated breast cancer aged 36 to 50 (7% to 8% prevalence in both TNBC and non-TNBC).
For the T[5-Me,8]G cross-link, a similar pattern of mutations was noted, but the mutational frequency was significantly higher than that of G[8,5-Me]T.
